{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:26:53Z","timestamp":1786739213070,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:p>\n                    Migraines represent a significant health burden globally and are particularly prevalent in Saudi Arabia, with rates exceeding the global average. Effective management of acute migraine attacks is crucial for improving patient outcomes. Ubrogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, has shown promise in treating acute migraines. While previous research has confirmed its efficacy and safety in different populations, there is a lack of localized data evaluating its use among patients in Saudi Arabia. To evaluate the efficacy, safety, and tolerability of Ubrogepant 100 mg for acute migraine management among patients in Hail City, Saudi Arabia. This retrospective case series included all patients prescribed Ubrogepant 100 mg for acute migraine attacks. Eligible patients were identified through electronic medical records and contacted via patient portal, phone, or clinic visits to complete a 15-item open-ended questionnaire. The survey assessed treatment response, safety, and tolerability of Ubrogepant. Among 27 migraine patients treated with Ubrogepant, nearly 70% achieved complete headache resolution within 2 hours, and 80% experienced significant migraine relief within 1.5 hours. Functional disability scores significantly improved (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .001), and associated symptoms such as photophobia and nausea also declined. While nearly half (48%) experienced mild side effects, mostly fatigue, more than half reported no adverse events. Ubrogepant 100 mg was effective and well-tolerated for acute migraine treatment, with most patients experiencing pain relief and improved function within 2 hours. Most reported no side effects, supporting its use as a safe treatment option for acute migraine.\n                  <\/jats:p>","DOI":"10.4103\/jfmpc.jfmpc_2110_25","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T14:01:14Z","timestamp":1779544874000},"page":"1819-1826","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy, safety, and tolerability of ubrogepant in the treatment of acute migraine among migraine patients in Hail City, Saudi Arabia: A retrospective case"],"prefix":"10.4103","volume":"15","author":[{"given":"Walid","family":"Alesefir","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Hail, Hail, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumayyah M.","family":"Almarshedy","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Hail, Hail, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Almarshadi","sequence":"additional","affiliation":[{"name":"Public Health Department, University of Hail, Hail, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed","family":"Alabdali","sequence":"additional","affiliation":[{"name":"Department of Neurology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alghassab","sequence":"additional","affiliation":[{"name":"Urology Department, King Saud Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Alyateem","sequence":"additional","affiliation":[{"name":"Physical and Rehabilitation Medicine Department, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turki","family":"Alshammari","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jassam","family":"Alessa","sequence":"additional","affiliation":[{"name":"Neurology Department, King Fahad Hospital, Hofuf, Al-Ahsa, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed Abdulllah","family":"Alzahrani","sequence":"additional","affiliation":[{"name":"General Surgery Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"R1-20260603","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Migraine remains second among the world's causes of disability, and first among young women: Findings from GBD2019","volume":"21","author":"Steiner","year":"2020","journal-title":"J Headache Pain"},{"key":"R2-20260603","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s10194-020-1081-1","article-title":"The prevalence of primary headache disorders in Saudi Arabia: A cross-sectional population-based study","volume":"21","author":"Al Jumah","year":"2020","journal-title":"J Headache Pain"},{"key":"R3-20260603","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1001\/jama.2021.1640","article-title":"Diagnosis and management of headache: A review","volume":"325","author":"Robbins","year":"2021","journal-title":"JAMA"},{"key":"R4-20260603","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1046\/j.1526-4610.2001.041007638.x","article-title":"Migraine diagnosis and treatment: Results from the American Migraine Study II","volume":"41","author":"Lipton","year":"2001","journal-title":"Headache"},{"key":"R5-20260603","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N Engl J Med"},{"key":"R6-20260603","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of Ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: The ACHIEVE II randomized clinical trial","volume":"322","author":"Lipton","year":"2019","journal-title":"JAMA"},{"key":"R7-20260603","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40265-020-01264-5","article-title":"Ubrogepant: First approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"R8-20260603","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s10194-024-01718-1","article-title":"Clinical features of migraine with aura: A REFORM study","volume":"25","author":"Thomsen","year":"2024","journal-title":"J Headache Pain"},{"key":"R9-20260603","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/head.13459","article-title":"Migraine progression: A systematic review","volume":"59","author":"Buse","year":"2019","journal-title":"Headache"},{"key":"R10-20260603","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1212\/WNL.0000000000001256","article-title":"Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine","volume":"84","author":"Lipton","year":"2015","journal-title":"Neurology"},{"key":"R11-20260603","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1001\/jama.2021.7939","article-title":"Acute treatments for episodic migraine in adults: A systematic review and meta-analysis","volume":"325","author":"VanderPluym","year":"2021","journal-title":"JAMA"},{"key":"R12-20260603","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/practneurol-2018-002048","article-title":"Medication-overuse headache","volume":"19","author":"Wakerley","year":"2019","journal-title":"Pract Neurol"},{"key":"R13-20260603","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s10194-024-01755-w","article-title":"Medication-overuse headache: A narrative review","volume":"25","author":"Gosalia","year":"2024","journal-title":"J Headache Pain"},{"key":"R14-20260603","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N Engl J Med"},{"key":"R15-20260603","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0333102416678382","article-title":"Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis","volume":"37","author":"Hepp","year":"2017","journal-title":"Cephalalgia"},{"key":"R16-20260603","doi-asserted-by":"crossref","first-page":"5762","DOI":"10.1007\/s00415-024-12512-z","article-title":"Effectiveness and safety of pharmacological prophylaxis for chronic migraine: A systematic review and network meta-analysis","volume":"271","author":"Zhao","year":"2024","journal-title":"J Neurol"},{"key":"R17-20260603","doi-asserted-by":"crossref","first-page":"e209745","DOI":"10.1212\/WNL.0000000000209745","article-title":"Effect of Ubrogepant on patient-reported outcomes when administered during the migraine prodrome: Results from the randomized PRODROME trial","volume":"103","author":"Lipton","year":"2024","journal-title":"Neurology"},{"key":"R18-20260603","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","article-title":"Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxinA: A retrospective chart review","volume":"10","author":"Blumenfeld","year":"2021","journal-title":"Pain Ther"},{"key":"R19-20260603","first-page":"145","article-title":"Medication overuse and drug addiction: A narrative review from addiction perspective","volume":"13","author":"Vernieri","year":"2021","journal-title":"Drug Healthc Patient Saf"},{"key":"R20-20260603","first-page":"1","article-title":"The American Headache Society position statement on integrating new migraine treatments into clinical practice","volume":"59","year":"2019","journal-title":"Headache"},{"key":"R21-20260603","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1526-4610.1995.hed3507387.x","article-title":"Migraine symptoms: Results of a survey of self-reported migraineurs","volume":"35","author":"Silberstein","year":"1995","journal-title":"Headache"},{"key":"R22-20260603","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1046\/j.1526-4610.1997.3710615.x","article-title":"Neurotology of migraine","volume":"37","author":"Baloh","year":"1997","journal-title":"Headache"},{"key":"R23-20260603","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0333102415620251","article-title":"Premonitory symptoms in migraine: A cross-sectional study in 2714 persons","volume":"36","author":"Laurell","year":"2016","journal-title":"Cephalalgia"},{"key":"R24-20260603","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0025-6196(11)60561-2","article-title":"Assessing and managing all aspects of migraine: Migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life","volume":"84","author":"Buse","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"R25-20260603","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/13543784.2019.1618830","article-title":"Gepants for the treatment of migraine","volume":"28","author":"Negro","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"R26-20260603","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1526-4610.2011.02058.x","article-title":"Pharmacological synergy: The next frontier on therapeutic advancement for migraine","volume":"52","author":"Blumenfeld","year":"2012","journal-title":"Headache"},{"key":"R27-20260603","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s00415-014-7603-5","article-title":"Assessment of cognitive dysfunction during migraine attacks: A systematic review","volume":"262","author":"Gil-Gouveia","year":"2015","journal-title":"J Neurol"},{"key":"R28-20260603","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/head.13766","article-title":"Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, ACHIEVE I and II","volume":"60","author":"Dodick","year":"2020","journal-title":"Headache"},{"key":"R29-20260603","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ncl.2019.07.006","article-title":"Acute Treatment of Migraine","volume":"37","author":"Tepper","year":"2019","journal-title":"Neurol Clin"},{"key":"R30-20260603","doi-asserted-by":"crossref","DOI":"10.1080\/14740338.2025.2497394","article-title":"Identifying signals of disproportionate reporting for calcitonin gene-related peptide inhibitors: real-world evidence from the FDA adverse event reporting system","author":"Lee","year":"2025","journal-title":"Expert Opin Drug Saf. Published online April 28,"},{"key":"R31-20260603","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/head.12601","article-title":"Triptans in the acute treatment of migraine: A systematic review and network meta-analysis","volume":"55","author":"Cameron","year":"2015","journal-title":"Headache"},{"key":"R32-20260603","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.01.005","article-title":"Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?","volume":"186","author":"Rubio-Beltr\u00e1n","year":"2018","journal-title":"Pharmacol Ther"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_2110_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:26:48Z","timestamp":1786735608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_2110_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_2110_25","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-12-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}